Eris Lifesciences Limited reported strong financial results for the quarter and year ended March 31, 2026. The Board of Directors declared an interim dividend of Rs 7.21 per share for the financial year 2026-2027. Consolidated net profit for the year reached Rs 647.51 crore, marking a significant growth compared to the previous year. The record date for the dividend is set for May 29, 2026, with payment scheduled by June 19, 2026.
Financial Performance Highlights
For the financial year ended March 31, 2026, Eris Lifesciences recorded a consolidated net profit of Rs 647.51 crore, up from Rs 374.67 crore in the previous fiscal year. Total revenue from operations for FY2026 stood at Rs 3,129.42 crore. The quarterly performance for Q4 FY2026 reflected a net profit of Rs 279.10 crore on revenues of Rs 756.56 crore, showcasing robust operational efficiency.
Strategic Acquisitions and Developments
The company continued its expansion strategy during the year. On January 16, 2026, Eris completed the acquisition of all remaining minority shares in Swiss Parenteral Limited (SPL), making it a wholly-owned subsidiary. Furthermore, on March 31, 2026, the company successfully completed the acquisition of the Branded Probiotics Business from Velbiom Probiotics Private Limited for a consideration of Rs 50 crore on a slump sale basis.
Dividend and Shareholder Information
The Board of Directors has approved an interim dividend of Rs 7.21 per share (a 721% payout) on equity shares with a face value of Re 1 each for the financial year 2026-2027. Investors looking to participate in this dividend must hold shares as of the record date, May 29, 2026. Eligible shareholders can expect the dividend payment to be credited on or before June 19, 2026.
Impact of Regulatory and Tax Changes
During the period, the company navigated significant legislative changes. The implementation of the ‘New Labour Codes’ resulted in a one-time impact of Rs 17.24 crore on gratuity and leave liabilities, which was categorized as an exceptional item. Conversely, the company benefited from a deferred tax credit of Rs 150 crore due to the re-measurement of assets and liabilities following the decision to opt for a concessional tax regime from the upcoming financial year.
Source: BSE
